Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

264 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.
Broijl A, Kersten MJ, Alemayehu WG, Levin MD, de Weerdt O, Vellenga E, Meijer E, Wittebol S, Tanis BC, Cornelisse PB, Stevens-Kroef M, Bos GM, Wijermans PW, Lokhorst H, Sonneveld P. Broijl A, et al. Among authors: lokhorst h. Haematologica. 2016 Apr;101(4):e149-52. doi: 10.3324/haematol.2015.132431. Epub 2015 Dec 11. Haematologica. 2016. PMID: 26659914 Free PMC article. Clinical Trial. No abstract available.
Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial.
Sonneveld P, van der Holt B, Segeren CM, Vellenga E, Croockewit AJ, Verhoe GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW, Westveer PH, Lokhorst HM; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Sonneveld P, et al. Among authors: lokhorst hm. Haematologica. 2007 Jul;92(7):928-35. doi: 10.3324/haematol.11168. Haematologica. 2007. PMID: 17606443 Free article. Clinical Trial.
Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology.
Hazenberg BP, Croockewit A, van der Holt B, Zweegman S, Bos GM, Delforge M, Raymakers RA, Sonneveld P, Vellenga E, Wijermans PW, von dem Borne PA, van Oers MH, de Weerdt O, Spoelstra FM, Lokhorst HM; Dutch-Belgian Cooperative Trial Group for Hematology Oncology. Hazenberg BP, et al. Among authors: lokhorst hm. Haematologica. 2015 May;100(5):677-82. doi: 10.3324/haematol.2014.119198. Epub 2015 Feb 6. Haematologica. 2015. PMID: 25661441 Free PMC article. Clinical Trial.
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.
Nijhof IS, Franssen LE, Levin MD, Bos GMJ, Broijl A, Klein SK, Koene HR, Bloem AC, Beeker A, Faber LM, van der Spek E, Ypma PF, Raymakers R, van Spronsen DJ, Westerweel PE, Oostvogels R, van Velzen J, van Kessel B, Mutis T, Sonneveld P, Zweegman S, Lokhorst HM, van de Donk NWCJ. Nijhof IS, et al. Blood. 2016 Nov 10;128(19):2297-2306. doi: 10.1182/blood-2016-07-729236. Epub 2016 Sep 19. Blood. 2016. PMID: 27647864 Free article. Clinical Trial.
Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial.
Wester R, van der Holt B, Asselbergs E, Zweegman S, Kersten MJ, Vellenga E, van Marwijk Kooy M, de Weerdt O, Minnema M, Lonergan S, Palumbo A, Lokhorst H, Broijl A, Sonneveld P. Wester R, et al. Among authors: lokhorst h. Haematologica. 2019 Nov;104(11):2265-2273. doi: 10.3324/haematol.2018.205476. Epub 2019 Apr 4. Haematologica. 2019. PMID: 30948492 Free PMC article. Clinical Trial.
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma.
Lokhorst HM, Schmidt-Wolf I, Sonneveld P, van der Holt B, Martin H, Barge R, Bertsch U, Schlenzka J, Bos GM, Croockewit S, Zweegman S, Breitkreutz I, Joosten P, Scheid C, van Marwijk-Kooy M, Salwender HJ, van Oers MH, Schaafsma R, Naumann R, Sinnige H, Blau I, Delforge M, de Weerdt O, Wijermans P, Wittebol S, Duersen U, Vellenga E, Goldschmidt H; Dutch-Belgian HOVON; German GMMG. Lokhorst HM, et al. Haematologica. 2008 Jan;93(1):124-7. doi: 10.3324/haematol.11644. Haematologica. 2008. PMID: 18166796 Free article. Clinical Trial.
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.
Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH, von dem Borne P, Wijermans P, Schaafsma R, de Weerdt O, Wittebol S, Delforge M, Berenschot H, Bos GM, Jie KS, Sinnige H, van Marwijk-Kooy M, Joosten P, Minnema MC, van Ammerlaan R, Sonneveld P; Dutch-Belgian Hemato-Oncology Group (HOVON). Lokhorst HM, et al. Blood. 2010 Feb 11;115(6):1113-20. doi: 10.1182/blood-2009-05-222539. Epub 2009 Oct 30. Blood. 2010. PMID: 19880501 Free article. Clinical Trial.
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.
Kneppers E, van der Holt B, Kersten MJ, Zweegman S, Meijer E, Huls G, Cornelissen JJ, Janssen JJ, Huisman C, Cornelisse PB, Bruijnen CP, Emmelot M, Sonneveld P, Lokhorst HM, Mutis T, Minnema MC. Kneppers E, et al. Blood. 2011 Sep 1;118(9):2413-9. doi: 10.1182/blood-2011-04-348292. Epub 2011 Jun 20. Blood. 2011. PMID: 21690556 Free article. Clinical Trial.
264 results